Table 1.
Summary of results reported for those outcome measures and endpoints identified as of primary interest by authors, following a single dose (SD) and repeated dose (RD)
| 80 mg | 160 mg | 320 mg | 640 mg | 960 mg | ||||||
|---|---|---|---|---|---|---|---|---|---|---|
| SD | RD | SD | RD | SD | RD | SD | RD | SD | RD | |
| Blood pressure | — | — | ↑p | — | ↑p | — | — | — | — | — |
| Heart rate | — | ↑pb.i.d | — | — | ↑p | — | — | — | — | — |
| Spontaneous platelet aggregation | — | — | ↑p | — | ↑p | — | — | — | — | — |
| Cutaneous erythrocyte velocity in capillaries | — | — | — | — | ↑p | — | — | — | — | — |
| Cerebral blood flow | — | — | — | ↑pb.i.d | — | — | — | — | — | — |
| Concentration | — | — | — | ↑pb.i.d | — | — | — | — | — | — |
| Visual scanning | — | — | — | ↑pb.i.d | — | — | — | — | — | — |
| Quality‐of‐memory Index (accuracy) | — | — | — | — | — | ↑pb.i.d/↑h | — | — | ↑h | — |
| Quality‐of‐memory Index (speed) | — | — | — | ↑pb.i.d | — | — | — | — | — | — |
| Secondary memory sub‐factor | — | — | — | — | — | — | — | — | ↑h | — |
| Speed of attention | — | — | — | — | ↓h | — | ↓h | — | — | — |
| Mental arithmetic | — | — | — | — | ↑h | — | ↑h | — | ↑h | — |
Upward arrow indicated benefit for treatment over placebo whereas a downward arrow indicates a decrement for treatment. Sample population is indicted by “p” (patient) and “h” (healthy). Dose was taken in a single ingestion unless stated (b.i.d—twice per day). As an example, 80 mg, consumed twice per day (daily dose equates to 160 mg) of repeated ingestion improved heart rate, in a patient population, relative to placebo.